These innovative molecules represent a significant advancement in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose https://tayaxtpn245893.blogolenta.com/36152615/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide